Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) appointed Nathaniel "Nate" Sisitsky as Chief Legal Officer, effective March 23, 2026. He will report to CEO Brian Blaser and lead global legal, compliance and corporate governance functions.

Mr. Sisitsky has 25+ years of legal experience across life sciences and technology, most recently serving as Chief Legal Officer and Corporate Secretary at STAAR Surgical. Michelle Hodges is retiring and will advise during the transition.

News Market Reaction – QDEL

-2.30%

-2.30% Session close to close

In the Mar 24 session, QDEL declined 2.30%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a senior legal leadership transition, with an experienced Chief Legal O...

Analysis

This announcement highlights a senior legal leadership transition, with an experienced Chief Legal Officer taking over global legal, compliance, and governance functions effective March 23, 2026. It follows a period marked by significant financial reporting events and strategic adjustments. Investors may monitor how this hire supports ongoing transformation, interacts with existing executive changes, and contributes to risk management and regulatory navigation, especially given the company’s prior goodwill impairment and evolving diagnostics portfolio.

Key Figures

Legal experience: more than 25 years

1 metrics

Legal experience more than 25 years Public company legal and governance roles

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 19	Podcast episode	Neutral	-2.3%	Science Bytes episode on high‑sensitivity troponin for earlier cardiac detection.
Feb 18	Conference appearance	Neutral	-2.3%	Announcement of presentation at Raymond James Institutional Investor Conference.
Feb 11	Earnings results	Negative	-17.6%	FY25 results with $701M goodwill impairment and FY26 guidance details.
Feb 3	Industry awards	Positive	+1.2%	Excellence Services Label in EMEA plus Gold and Bronze Stevie awards.
Jan 22	Podcast episode	Neutral	+3.9%	Science Bytes episode on blood supply challenges and donor engagement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows negative reactions to neutral events and a sharp selloff on earnings, with only modest gains on awards news. Against this backdrop, today’s strong positive move on an executive appointment contrasts with prior muted or negative responses to standard corporate updates.

Recent Company History

Over the past few months, QuidelOrtho has issued a mix of operational and investor-relations updates, including two Science Bytes podcasts on Jan 22 and Feb 19, a conference appearance announcement on Feb 18, industry recognition with service and Stevie awards on Feb 3, and detailed Q4/FY25 results on Feb 11. Earnings highlighted a large goodwill impairment and a significant one-day drop of -17.59%. Most non-earnings news produced relatively small moves, suggesting today’s leadership announcement comes after a stretch of cautious trading around company communications.

Key Terms

in vitro diagnostics, medtech sector

2 terms

in vitro diagnostics medical

"QuidelOrtho Corporation (Nasdaq: QDEL) ..., a global leader of in vitro diagnostics, is pleased..."

In vitro diagnostics are medical tests performed on samples taken from the body—such as blood, urine or tissue—using instruments or kits outside the patient to detect disease, measure biomarkers or guide treatment decisions. They matter to investors because sales, regulatory approvals, reimbursement rules and adoption rates drive companies’ revenue and margins much like product launches and consumer demand in other industries; advances can create growth or disruption in healthcare markets.

medtech sector technical

"Throughout his career, Mr. Sisitsky has provided legal leadership ... across the medtech sector."

Medtech sector comprises companies that design, manufacture and sell medical devices, diagnostic tests, health-monitoring equipment and the software that runs them — the tangible tools used to detect, treat or manage health conditions. Investors watch medtech because product approvals, hospital adoption, and reimbursement decisions drive sales and valuation; it's like backing a new, improved tool that can replace older methods and create steady revenue or sudden growth when widely adopted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions.

Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors. Most recently, he served as Chief Legal Officer and Corporate Secretary at STAAR Surgical Company, where he oversaw global legal and compliance functions.

"Nate is a seasoned legal executive with deep experience navigating complex public company environments," said Brian Blaser, President and Chief Executive Officer, QuidelOrtho. "He brings a thoughtful, business-oriented approach to legal leadership and a strong track record of guiding organizations through transformations, governance matters and global regulatory matters. We are pleased to welcome him to QuidelOrtho as we continue advancing our strategy and strengthening our foundation for long-term growth."

Mr. Sisitsky succeeds Michelle Hodges, who is retiring after a distinguished career and years of service to QuidelOrtho. Ms. Hodges played an important role in strengthening the Company's legal and governance capabilities, supporting strategic initiatives and guiding the organization through a period of significant transformation. Ms. Hodges will serve in an advisory role to facilitate a smooth transition.

Throughout his career, Mr. Sisitsky has provided legal leadership during periods of significant organizational change across the medtech sector. His roles as Senior Vice President, General Counsel and Corporate Secretary at NuVasive, Inc. and CareFusion Corporation included guiding legal and compliance functions through major corporate transitions, ensuring continuity and strategic alignment across global operations.

"I'm excited to join QuidelOrtho and contribute to a company that plays such a vital role in global healthcare," said Mr. Sisitsky. "Diagnostics are essential to informed medical decision-making, and QuidelOrtho has an important opportunity to continue advancing innovation that improves patient care worldwide. I look forward to working alongside Brian and the leadership team to support the Company's mission and long-term growth."

Mr. Sisitsky began his legal career at Wilmer Cutler Pickering Hale and Dorr LLP. He later served in senior legal roles at American Tower Corporation before moving into leadership positions across the medical technology sector. He holds a Juris Doctor from New York University School of Law and a Bachelor of Arts in Political Science and Economics from Emory University. 

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer-302722706.html

SOURCE QuidelOrtho Corporation

FAQ

Who is Nathaniel Sisitsky and what role did he accept at QuidelOrtho (QDEL)?

He is the new Chief Legal Officer at QuidelOrtho, effective March 23, 2026. According to the company, Mr. Sisitsky will lead global legal, compliance and corporate governance and report to CEO Brian Blaser, bringing over 25 years of public-company legal experience.

When did Nathaniel Sisitsky start as Chief Legal Officer at QuidelOrtho (QDEL)?

Mr. Sisitsky's appointment became effective March 23, 2026. According to the company, he assumed leadership of global legal, compliance and corporate governance functions on that date to support ongoing strategy.

Who did Nathaniel Sisitsky succeed as Chief Legal Officer at QuidelOrtho (QDEL)?

He succeeds Michelle Hodges, who is retiring from her role. According to the company, Ms. Hodges will remain in an advisory role to ensure a smooth transition during the leadership change.

What is Nathaniel Sisitsky's legal and industry background before joining QuidelOrtho (QDEL)?

He has over 25 years advising public companies in life sciences and technology. According to the company, his prior roles include Chief Legal Officer at STAAR Surgical and senior legal positions at NuVasive and CareFusion.

To whom will Nathaniel Sisitsky report at QuidelOrtho (QDEL)?

He will report to Brian Blaser, President and CEO. According to the company, Mr. Sisitsky will work with the leadership team to support governance, compliance and the company's long-term strategy.

What qualifications does Nathaniel Sisitsky hold relevant to his role at QuidelOrtho (QDEL)?

He holds a Juris Doctor from New York University School of Law and a BA from Emory University. According to the company, his academic and extensive in-house experience support his leadership of global legal and compliance functions.